trial · primary record
Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center
Lupus Erythematosus, Systemic
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 16 |
| Primary completion | 2028-10-01 |
| Primary endpoint | Incidence and Severity of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) |
| Registry ID | NCT07659704 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:39.669Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07659704
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.